Cargando…

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps

BACKGROUND: Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and efficacy in a real-world setting. This study aims to assess how clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilty, Shaun J., Lasso, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036753/
https://www.ncbi.nlm.nih.gov/pubmed/35468866
http://dx.doi.org/10.1186/s40463-022-00570-0